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Additional file1: Figure S1.  No significant correlation between age and HERV-K gag, pol and env RNA 
relative expression levels whether normalised by GAPDH or XPNPEP1. Data from all 34 ALS and 23 non-
ALS controls are presented. a, b, c normalised against GAPDH;  d, e, f normalised against XPNPEP1.  R-
squared coefficient of determination values calculated in Microsoft Excel.  All p values are >0.05 by linear 











Additional file1: Figure S2.  No significant correlation between gender and HERV-K RNA expression 
whether normalised by GAPDH or XPNPEP1.  Data from all 34 ALS and 23 non-ALS controls are 
presented.  a, b, c normalised against GAPDH;  d, e, f normalised against XPNPEP1.  All p values are 



































































































































































































Additional file1: Figure S3.  Correlation between high postmortem delay (PMD) and reduced relative 
HERV-K RNA expression reaches statistical significance for pol and env whether normalised by GAPDH or 
XPNPEP1.  Data from all 34 ALS and 23 non-ALS controls are presented.  a, b, c normalised against 
GAPDH;  d, e, f normalised against XPNPEP1.  R-squared coefficient of determination values calculated in 










Additional file1: Figure S4.  Correlation between RNA integrity number (RIN) and HERV-K gag, pol and 
env RNA relative expression levels.  Data from all 34 ALS and 23 non-ALS controls are presented.  a, b, c 
normalised against GAPDH;  d, e, f normalised against XPNPEP1.  R-squared coefficient of determination 











Additional file1: Figure S5.  HERV-W env RNA relative expression shows no significant correlation with 
age.  Data from all 34 ALS and 23 non-ALS controls are presented.  a, GAPDH normalised, b XPNPEP1 
normalised.  R-squared coefficient of determination values calculated in Microsoft Excel.  Both p values are 










Additional file1: Figure S6.  HERV-W env RNA relative expression shows no significant correlation with 
gender.  Data from all 34 ALS and 23 non-ALS controls are presented.  a, GAPDH normalised, b 






































































Additional file1: Figure S7.  HERV-W env RNA relative expression correlated with postmortem delay 
(PMD).  Data from all 34 ALS and 23 non-ALS controls are presented.  a, GAPDH normalised, b XPNPEP1 
normalised.  R-squared coefficient of determination values calculated in Microsoft Excel.  Linear regression 











Additional file1: Figure S8.  HERV-W env RNA relative expression correlated with RNA integrity number 
(RIN).  Data from all 34 ALS and 23 non-ALS controls are presented.  a, GAPDH normalised, b XPNPEP1 
normalised.  R-squared coefficient of determination values calculated in Microsoft Excel.  Linear regression 







Additional file1: Figure S9.  Correlation between GAPDH and XPNPEP1 normalised HERV-K and HERV-
W RNA relative expression levels.  Parts a, b and c represent HERV-K gag, pol and env respectively.  Part 
d represents HERV-W env.  Data from all 34 ALS and 23 non-ALS controls are presented.  R-squared 






Additional file1: Figure S10.  No correlation between RNA integrity number (RIN) and post mortem delay 
(PMD).  Data from all 34 ALS and 23 non-ALS controls are presented.  R-squared coefficient of 





Additional file1: Figure S11.  Relative expression levels of HERV-K gag, pol and env RNA, and HERV-W 
env RNA in 34 ALS and 12 non-ALS controls without cancer.  a, b, c and d normalised against GAPDH;  e, 
f, g and h normalised against XPNPEP1.  Horizontal black lines represent geometric means.  All p values 




































































































































































































































Additional file1: Table S1.  Clinical details of ALS cases and controls 







 F 54 67.5 6.8 
ALS #2 ALS F 65 68 6.7 
ALS #3 ALS F 73 70 6.5 
ALS #4 ALS M 65 16 8.2 
ALS #5 ALS F 62 70 7.2 
ALS #6 ALS F 68 64 7.4 
ALS #7 ALS M 78 79 6.2 
ALS #8 ALS M 77 66 6.3 
ALS #9 ALS M 66 46 8.0 
ALS #10 ALS M 65 33 7.3 
ALS #11 ALS M 65 64 6.5 
ALS #12 ALS F 68 57 6.0 
ALS #13 ALS F 63 25 5.5 
ALS #14 ALS M 68 73 5.5 
ALS #15 ALS F 72 74 6.7 
ALS #16 ALS M 75 42 5.7 
ALS #17 ALS M 64 51 6.5 
ALS #18 ALS M 53 69 7.2 
ALS #19 ALS M 66 59 6.8 
ALS #20 ALS M 72 89 5.5 
ALS #21 ALS   M 72 26 6.0 
ALS #22 ALS M 74 19 6.5 
ALS #23 ALS M 75 20 5.0 
ALS #24 ALS M 82 12.5 6.7 
ALS #25 ALS M 75 6.5 6.5 
ALS #26 ALS M 68 14 7.2 
ALS #27 ALS F 79 35 6.2 
ALS #28 ALS M 75 98 5.6 
ALS #29 ALS M 68 5.2 6.1 
ALS #30 ALS M 55 4.5 6.7 
ALS #31 ALS M 60 11 6.9 
ALS #32 ALS F 49 64 5.9 
ALS #33 ALS  M 50 26 7.5 
ALS #34 ALS M 54 69 6.8 
Control #1 metastatic ovarian cancer F 68 58.5 6.2 
Control #2 lung cancer F 52 44 6.7 
Control #3 myocardial infarction M 61 53 6.0 
Control #4 renal cancer F 77 21 6.2 
Control #5 carcinomatous meningitis M 54 30 6.6 
Control #6 aortic sclerosis; infection F 89 41 6.0 
Control #7 myocardial infarction M 67 41 5.6 
Control #8 cancer; unknown primary M 80 48.25 5.1 
Control #9 gastric & bronchial carcinoma F 58 21 6.0 
Control #10 myocardial infarction F 55 95 6.0 
Control #11 prostate cancer M 65 26 7.0 
Control #12 breast cancer F 85 45 5.8 
Control #13 cerebral infarction M 83 48 6.9 
Control #14 renal cancer M 78 30.5 5.4 
Control #15 peritonitis & septicaemia M 79 24 5.1 
Control #16 cardiac problems & prostate cancer M 80 55 6.4 
Control #17 chronic obstructive pulmonary disease F 84 35 6.1 
Control #18 cerebral infarction M 81 18 5.1 
Control #19 myocardial infarction & pneumonia M 89 84 5.9 
Control #20 asthma attack F 88 39 6.4 
Control #21 cancer; unknown primary F 80 3 6.4 
Control #22 syringomyelia M 55 24 5.6 
Control #23 natural causes
d
 F 83 74 6.6 
a
PMD - postmortem delay   
b
RIN - RNA integrity number   
c
ALS - all ALS cases in this study were apparently sporadic   
d
Natural causes - details unavailable (clinically bipolar affective disorder)  
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Additional file1: Table S2.   MIQE Checklist 
 
MIQE checklist for authors, reviewers and editors.  
All essential information (E) must be submitted with the manuscript.  Desirable information (D) 
should be submitted if possible.  
If using primers obtained from RTPrimerDB, information on qPCR target, oligonucleotides, protocols 
and validation is available from that source. 
 
ITEM TO CHECK IMPORTANCE Comments 
EXPERIMENTAL DESIGN   
Definition of experimental and control  groups E Materials & Methods; Table S1 
Number within each group E 34 ALS & 23 controls 
Assay carried out by core lab or investigator's lab? D Investigator’s lab 
Acknowledgement of authors' contributions  D  
SAMPLE   
Description E Frozen postmortem brain tissue 
     Volume/mass of sample processed D 60 mg 
    Microdissection or macrodissection E macro 
Processing procedure E Materials & Methods 
     If frozen - how and how quickly? E Frozen at -80 oC after post-mortem 
delay as detailed in Table S1 
     If fixed - with what, how quickly? E unfixed 
Sample storage conditions and duration (especially 
for FFPE samples) 
E Stored at -80 oC in MRC brain bank 
NUCLEIC ACID EXTRACTION   
Procedure and/or instrumentation E  
     Name of kit and details of any modifications E RNeasy Lipid Tissue kit (Qiagen) 
     Source of additional reagents used  D Materials & Methods 
Details of DNase or RNAse treatment E on-column DNase treatment (RNase-
free DNase Set, Qiagen 
Contamination assessment (DNA or RNA) E DNA contamination assessment by 
qPCR without RT step 
Nucleic acid quantification  E RNA quantification performed 
     Instrument and method E Qubit™ RNA BR assay (Thermo 
Fisher Scientific Inc) 
     Purity (A260/A280)  D Assessed by NanoDrop™ (Thermo 
Fisher Scientific Inc) 
     Yield D  
RNA integrity method/instrument E Agilent RNA 6000 Nano assay 
(Agilent Technologies, Inc.) 
    RIN/RQI or Cq of 3' and 5' transcripts  E RIN values detailed in Table S1 
    Electrophoresis traces D Agilent RNA 6000 Nano assay 
(Agilent Technologies, Inc.) 
 Inhibition testing (Cq dilutions, spike or other)  E ND† 
REVERSE TRANSCRIPTION   
Complete reaction conditions E Materials & Methods 
     Amount of RNA and reaction volume E 1 µg of RNA in a 20 µl reaction 
    Priming oligonucleotide (if using GSP) and 
concentration 
E 2X RT Reaction Mix includes 
oligo(dT)20 (2.5 μM) & random 
hexamers (2.5 ng/μL) 
     Reverse transcriptase and concentration E Invitrogen SuperScript III First-Strand 
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Synthesis Supermix for qRT-PCR 
     Temperature and time E According to manufacturer’s 
instructions 
     Manufacturer of reagents and catalogue 
numbers 
D SuperScript III First-Strand Synthesis 
Supermix for qRT-PCR  
Thermo Fisher   Cat No.11752-050 
Cqs with and without RT D* See Results for details 
Storage conditions of cDNA D cDNA stored at -20 oC 
qPCR TARGET INFORMATION   
If multiplex, efficiency and LOD of each assay. E Not multiplex. PCR efficiencies given 
in Results 
Sequence accession number E NA‡ 
Location of amplicon D Table 1 
     Amplicon length E Confirmed by electrophoresis & 
sequencing.  Available on request 
     In silico specificity screen (BLAST, etc) E Yes 
     Pseudogenes, retropseudogenes or other 
homologs? 
D  
          Sequence alignment D  
     Secondary structure analysis of amplicon D  
Location of each primer by exon or intron (if 
applicable) 
E NA‡ 
     What splice variants are targeted? E NA‡ 
qPCR OLIGONUCLEOTIDES   
Primer sequences E Table 1 
RTPrimerDB Identification Number  D  
Probe sequences D** NA‡ 
Location and identity of any modifications E none 
Manufacturer of oligonucleotides D Eurofins Genomics & Qiagen 
Purification method D  
qPCR PROTOCOL   
Complete reaction conditions E Materials and Methods 
     Reaction volume and amount of cDNA/DNA E 20 µl reaction with 2 µL cDNA 
     Primer, (probe), Mg++ and dNTP concentrations E 0.25 µM each primer 
     Polymerase identity and concentration  E Fast SYBR Green Master Mix 
(Thermo Fisher) 
     Buffer/kit identity and manufacturer  E Fast SYBR Green Master Mix 
(Thermo Fisher) 
     Exact chemical constitution of the buffer D Fast SYBR Green Master Mix 
(Thermo Fisher) 
     Additives (SYBR Green I, DMSO, etc.) E Fast SYBR Green Master Mix 
(Thermo Fisher) 
Manufacturer of plates/tubes and catalog number D Applied Biosystems MicroAmp Optical 
96-well reaction plate. no. N8010560 
Complete thermocycling parameters E Materials and Methods 
Reaction setup (manual/robotic) D manual 
Manufacturer of qPCR instrument E Applied Biosystems QuantStudio™ 5 
thermocycler 
qPCR VALIDATION   
Evidence of optimisation (from gradients)  D  
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Specificity (gel, sequence,  melt, or digest) E Confirmed by gel electrophoresis and 
sequencing 
For SYBR Green I, Cq of the NTC E NTC Cq >45 
Standard curves with slope and y-intercept E Available on request 
     PCR efficiency calculated from slope E Yes, see Results 
     Confidence interval for PCR efficiency or 
standard error 
D  
     r2 of standard curve E approximately 0.99 
Linear dynamic range E NA 
     Cq variation at lower limit E ND 
     Confidence intervals throughout range D  
Evidence for limit of detection  E NA 
If multiplex, efficiency and LOD of each assay. E Not multiplex 
DATA ANALYSIS   
qPCR analysis program (source, version) E QuantStudio Design and Analysis 
software v1.4.3 
     Cq method determination E Automatic baseline setting and 
manual threshold setting 
     Outlier identification and disposition E NA 
Results of NTCs  E >45 cycles 
Justification of number and choice of reference 
genes 
E Two reference gene transcripts used. 
Validation by qBase+ and RefFinder 
ranking of the nine candidates 
Description of normalisation method E 2-∆∆Ct method by normalisation against 
both GAPDH and XPNPEP1 
Number and concordance of biological replicates D  
Number and stage (RT or qPCR) of technical 
replicates 
E Materials and Methods 
Repeatability (intra-assay variation) E Standard deviation of duplicates <0.2 
Reproducibility (inter-assay variation, %CV) D  
Power analysis D  
Statistical methods for result significance E Materials and Methods 
   * Assessing the absence of DNA using a no RT 
assay is essential when first extracting RNA. Once 
the sample has been validated as DNA-free, 
inclusion of a no-RT control is desirable, but no 
longer essential. 
  ‡NA = not applicable 
  ** Disclosure of the probe sequence is highly 
desirable and strongly encouraged.  
  † ND = not done 







Additional file1: Table S3.   RefFinder rankings of candidate reference genes 
 
  Ranking Order (Better--Good--Average) 
Algorithm  1 2 3 4 5 6 7 8 9 
Delta CT XPNPEP1 CYC1 GAPDH ACTB SDHA UBC RPL13A EIF4A2 YWHAZ 
BestKeeper UBC SDHA RPL13A GAPDH XPNPEP1 CYC1 ACTB YWHAZ EIF4A2 
NormFinder XPNPEP1 CYC1 GAPDH ACTB SDHA UBC RPL13A EIF4A2 YWHAZ 
GeNorm SDHA | 
GAPDH 




XPNPEP1 GAPDH SDHA CYC1 UBC ACTB RPL13A EIF4A2 YWHAZ 
 
aThe recommended comprehensive ranking  generated by RefFinder is worked out based on the geometric 
mean of the stability ranking from all 4 algorithms; the comprehensive ranking lists XPNPEP1 and GAPDH 
as the 2 most stable reference genes. 
 
 
